Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus FLAREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus FLAREX.
DUREZOL vs FLAREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Corticosteroid that inhibits phospholipase A2 activity, reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes, thereby suppressing ocular inflammation.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
1-2 drops in the conjunctival sac every hour during the day and every 2 hours at night initially; after response, reduce to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
Terminal elimination half-life is approximately 1-2 hours (mean 1.3 hours) in adults. Due to rapid clearance, accumulation is minimal with topical ophthalmic dosing, but prolonged use may lead to systemic absorption and slightly extended half-life.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Primarily hepatic metabolism, with inactive metabolites excreted renally (approximately 60-80%) and fecally (20-40%). Less than 5% of unchanged drug appears in urine.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid